Next Article in Journal
Recurrent Laryngeal Nerve Preservation Strategies in Pediatric Thyroid Oncology: Continuous vs. Intermittent Nerve Monitoring
Next Article in Special Issue
Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects
Previous Article in Journal
Exosomes in Lung Cancer: Actors and Heralds of Tumor Development
Previous Article in Special Issue
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
Review

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New

1
Hematology and Medical Oncology Department, University Hospital Morales Meseguer, IMIB, 30003 Murcia, Spain
2
CB15/00055-CIBERER, 30003 Murcia, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Gabor Mikala
Cancers 2021, 13(17), 4332; https://doi.org/10.3390/cancers13174332
Received: 8 August 2021 / Revised: 20 August 2021 / Accepted: 23 August 2021 / Published: 27 August 2021
(This article belongs to the Special Issue Multiple Myeloma: Targeted Therapy and Immunotherapy)
Currently, response rates in multiple myeloma (MM) have increased dramatically, with more than 50% otablef those who respond satisfying complete response criteria. Achieving frequent deep responses has necessarily led to test conceptual advantages for assessing and treating MM patients with only minimal residual disease (MRD). In this review, we present and discuss the clinical relevance, methodology, and challenges for measuring MRD in MM.
The game-changing outcome effect, due to the generalized use of novel agents in MM, has cre-ated a paradigm shift. Achieving frequent deep responses has placed MM among those neoplasms where the rationale for assessing MRD is fulfilled. However, its implementation in MM has raised specific questions: how might we weight standard measures against deep MRD in the emerging CAR-T setting? Which high sensitivity method to choose? Are current response criteria still useful? In this work, we address lessons learned from the use of MRD in other neoplasms, the steps followed for the harmonization of current methods for comprehensively measuring MRD, and the challenges that new therapies and concepts pose in the MM clinical field. View Full-Text
Keywords: multiple myeloma; minimal residual disease; novel agents multiple myeloma; minimal residual disease; novel agents
Show Figures

Figure 1

MDPI and ACS Style

Bravo-Pérez, C.; Sola, M.; Teruel-Montoya, R.; García-Malo, M.D.; Ortuño, F.J.; Vicente, V.; de Arriba, F.; Jerez, A. Minimal Residual Disease in Multiple Myeloma: Something Old, Something New. Cancers 2021, 13, 4332. https://doi.org/10.3390/cancers13174332

AMA Style

Bravo-Pérez C, Sola M, Teruel-Montoya R, García-Malo MD, Ortuño FJ, Vicente V, de Arriba F, Jerez A. Minimal Residual Disease in Multiple Myeloma: Something Old, Something New. Cancers. 2021; 13(17):4332. https://doi.org/10.3390/cancers13174332

Chicago/Turabian Style

Bravo-Pérez, Carlos, María Sola, Raúl Teruel-Montoya, María D. García-Malo, Francisco J. Ortuño, Vicente Vicente, Felipe de Arriba, and Andrés Jerez. 2021. "Minimal Residual Disease in Multiple Myeloma: Something Old, Something New" Cancers 13, no. 17: 4332. https://doi.org/10.3390/cancers13174332

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop